Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome

2.1 Mogamulizumab (Poteligeo, Kyowa Kirin) is indicated for 'the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price of mogamulizumab is £1,329 per vial containing 4 mg of mogamulizumab per ml (excluding VAT; BNF online, accessed October 2021). The company has a commercial arrangement (simple discount patient access scheme). This makes mogamulizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.